“Byondis’ ambition is to become a leading pharmaceutical company by discovering, developing and delivering proprietary breakthrough medicinal modalities to patients in the field of cancer and other difficult to treat diseases. “
Jacques Lemmens, PhD, Founder / Chairman of the Board
Frequently Asked Questions (FAQ) for Investors
Is Byondis a privately owned company?
Byondis Holding B.V. is a private company with limited liability incorporated in the Netherlands. Byondis Holding and its subsidiaries, as a fully integrated biotech company, are mainly active in the field of research and development and production of innovative medicines.
When did Byondis begin operations?
Byondis started its biopharmaceutical activities in 2007 as Synthon Biopharmaceuticals, part of Synthon, a global leader in the development and manufacturing of complex generics. In 2012, the company became a new biopharmaceutical subsidiary and quickly built a promising pipeline of innovative research and development programs and rebranded itself as Byondis in April 2020.
Where is Byondis incorporated?
Byondis is incorporated in The Netherlands.
Where is Byondis headquartered?
Byondis is headquartered in Nijmegen, The Netherlands.
Registered address: Microweg 22 , 6545 CM Nijmegen, The Netherlands
Chamber of Commerce Byondis Holding: 10144473
Postal address:
P.O. Box 6570, 6503 GB Nijmegen, The Netherlands
What types of partnership opportunities does Byondis offer?
Byondis’s modular approach to ADC design enables broad partnering flexibility through co-development, licensing, and strategic collaboration. Our platform toolbox allows partners to select specific technologies - such as our novel payload platforms, masking technology, or linker and conjugation strategies - to address their unique therapeutic challenges. We’re open to exploring various partnership models for value creation.
What ADC platform technologies does Byondis have in its portfolio?
Byondis offers a comprehensive portfolio of differentiated ADC platform technologies that can work independently or in combination. These include: a first-in-class antifolate payload platform designed to overcome resistance to existing ADCs; a best-in-class steric masking technology providing a universal solution to reduce off-tumor toxicity; a first-in-class immunostimulatory phosphonate payload; and proprietary dual-payload systems with clinically validated conjugation and linker technologies to combine synergistic effects.
How can partners benefit from working with Byondis on ADC development?
Partners benefit from Byondis’s 20+ years of ADC expertise and proven ability to engineer ADCs that outperform current therapies. Our modular platforms can address multiple hallmarks of cancer, creating a multiplier effect that enables solutions beyond today’s therapeutic boundaries. Whether you’re seeking to overcome payload resistance, reduce off-tumor toxicity, or enhance immunotherapy response, our flexible platform approach allows you to select the technologies that best fit your therapeutic goals while leveraging our end-to-end development capabilities for efficient program advancement.
Where can I get the latest press releases?
Please visit our Press Release page on our Web site or sign-up for news alerts here.
Who should I contact if I have further questions?
Please contact Byondis’ investor relations at Investors@Byondis.com
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Who We Are
At Byondis, we are dedicated to transforming the lives of those affected by cancer.
